Travere Therapeutics (TVTX) Q3 2024 earnings summary

Executive summary

• FILSPARI received full FDA approval as the only non-immunosuppressive treatment for IgAN, driving strong commercial growth, expanded patient access, and over 30% sequential net sales growth; launches underway in the US and Europe, including Germany, Austria, and Switzerland.

• 505 new patient start forms for FILSPARI were received in Q3, with a total of 2,989 since launch in February 2023.

• Strategic reorganization in late 2023 reduced workforce by ~20%, targeting $25M in annualized savings.

• Sale of the bile acid business in August 2023 provided $210M upfront and potential $235M in milestones; business is now classified as discontinued operations.

• Enrollment in the Phase 3 HARMONY Study for pegtibatinase is paused for manufacturing improvements, with earliest restart in 2026.

Financial highlights

• Q3 2024 net product sales reached $61.0 million, up from $33.9 million in Q3 2023, an 80% year-over-year increase, with total revenue at $62.9 million.

• FILSPARI net product sales were $35.6 million in Q3, with year-to-date sales of $82.6 million.

• Q3 2024 net loss was $54.8 million ($0.70 per share), compared to net income of $150.7 million ($1.97 per share) in Q3 2023, reflecting the impact of discontinued operations.

• Non-GAAP adjusted net loss for Q3 2024 was $35.6 million ($0.46 per share), versus adjusted net income of $173.5 million ($2.27 per share) in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $277.4 million as of September 30, 2024.

Outlook and guidance

• Anticipates continued FILSPARI sales growth, supported by full approval, expanded label, and updated KDIGO guidelines.

• Expects to provide an update on FSGS regulatory discussions by Q4 earnings call, with potential sNDA submission and possible full approval in 2025.

• Cash use expected to decline over time, with operations supported into 2028.

• Management expects available cash and investments to fund operations beyond the next 12 months.

• Research and development expenses expected to decline in 2025 due to the HARMONY Study pause and completion of late-stage sparsentan trials.